Technical analysis of Celularity Inc. (CELU): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.
Price Performance
| 1 month | +75.11% |
| 3 months | +71.47% |
| Year-to-date | +16.22% |
| 1 year | -40.00% |
| 3 years | -50.95% |
| 5 years | -97.93% |
52-Week Range
| 52-week High | $2.55 |
| 52-week Low | $0.56 |
| Avg Volume (90d) | 2.8M |
Technical Indicators
| SMA 50 | $0.98 |
| SMA 200 | $1.12 |
| Beta | 0.70 |
| 30-day Volatility (annualised) | 277.1% |
| Price vs SMA 50 | +31.2% |
| Price vs SMA 200 | +14.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.95 | |
| 2025-11 | $2.00 | +2.6% |
| 2025-12 | $1.11 | -44.5% |
| 2026-01 | $1.22 | +9.9% |
| 2026-02 | $1.23 | +0.8% |
| 2026-03 | $1.33 | +8.1% |
| 2026-04 | $0.93 | -29.8% |
| 2026-05 | $1.01 | +8.1% |
| 2026-06 | $0.60 | -40.8% |
| 2026-07 | $0.64 | +6.3% |
| 2026-08 | $1.85 | +191.2% |
| 2026-09 | $1.29 | -30.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $0.03 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | $0.18 | $557M |
| 2026-09-14 | | |
| 2026-09-14 | | $1M |
| 2026-09-14 | | |
Price
| Price | $1.29 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.73 |
| EV / EBITDA | -0.91 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -1.07 |
| Current Ratio | 0.15 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -15.22 |